Gland Pharma Ltd

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Acetaminophen Injection, 500 mg/50 mL (10 mg/mL) and 1000 mg/100 mL (10 mg/mL), of B. Braun Medical, Inc. This product is indicated for the management of mild to moderate pain in adult and pediatric patients aged 2 years and older, as well as moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients aged 2 years and older. According to IQVIA, the product had US sales of approximately $55 million for the twelve months ending February 2025. The company expects to launch this product through its marketing partner in the near future. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. Gland Pharma's consolidated net profit increased 6.67% to Rs 204.70 crore despite a 10.42% decline in revenue from operations to Rs 1,384.1 crore in Q3 FY25 over Q3 FY25. Powered by Capital Market - Live

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Acetaminophen Injection, 10 mg/mL (500mg/50mL and 1000mg/100mL) Bags. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Acetaminophen Injection, 500 mg/50 mL (10 mg/mL) and 1000 mg/100 mL (10 mg/mL), of B. Braun Medical, Inc. This Product is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older, as well as moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older. The Company expects to launch this Product through its marketing partner in the near future. According to IQVIA, the product had US sales of approximately USD 55 million for the twelve months ending February 2025.Powered by Capital Market - Live

Gland Pharma Ltd gained 9.65% today to trade at Rs 1683.25. The BSE Healthcare index is up 2.92% to quote at 42322.92. The index is up 9.7 % over last one month. Among the other constituents of the index, Marksans Pharma Ltd increased 6.49% and Aurobindo Pharma Ltd added 5.74% on the day. The BSE Healthcare index went up 19.37 % over last one year compared to the 2.98% surge in benchmark SENSEX. Gland Pharma Ltd has added 10.42% over last one month compared to 9.7% gain in BSE Healthcare index and 4.23% rise in the SENSEX. On the BSE, 14825 shares were traded in the counter so far compared with average daily volumes of 8311 shares in the past one month. The stock hit a record high of Rs 2220.95 on 06 Aug 2024. The stock hit a 52-week low of Rs 1412 on 12 Feb 2025.Powered by Capital Market - Live

Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1537.85, down 1.01% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.55% on the day, quoting at 23293.85. The Sensex is at 76509.06, up 0.64%.Gland Pharma Ltd has eased around 0.06% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 5.1% in last one month and is currently quoting at 20771.8, up 0.58% on the day. The volume in the stock stood at 36116 shares today, compared to the daily average of 3.73 lakh shares in last one month.The PE of the stock is 22.85 based on TTM earnings ending December 24.Powered by Capital Market - Live

Gland Pharma has appointed Wriddhee Maitra as Vice-President (Human Resources), a Senior Management Personnel of the Company with effect from 10 March 2025.Powered by Capital Market - Live

Gland Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1663.3, up 2.05% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.03% on the day, quoting at 22550.8. The Sensex is at 74315, down 0.03%. Gland Pharma Ltd has gained around 12.55% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 5.76% in last one month and is currently quoting at 20423.35, down 0.03% on the day. The volume in the stock stood at 95455 shares today, compared to the daily average of 2.64 lakh shares in last one month.The PE of the stock is 23.95 based on TTM earnings ending December 24.Powered by Capital Market - Live

Gland Pharma has allotted 4,700 equity shares under ESOP on 26 February 2025. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs. 164,756,423/- comprising 164,756,423 equity shares of face value Re.1/- each. Powered by Capital Market - Live

Gland Pharma announced that the United States Food and Drug Administration (US FDA) has conducted a Pre-approval inspection (PAI) for Sterile APIs at the Company's Facility at JNPC, Visakhapatnam between 19 February 2025 and 25 February 2025. The said inspection was concluded with THREE (3) Form 483 Observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the US FDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity. Powered by Capital Market - Live

The inspection was conducted from 19 February 2025 to 25 February 2025. At the conclusion of the inspection, the USFDA issued a Form 483 with three observations. The company stated that these observations are procedural in nature, and it plans to submit corrective and preventive actions to the USFDA within the required time frame. The company further clarified that the observations are not repeated and are unrelated to any data integrity concerns. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. Gland Pharma's consolidated net profit increased 6.67% to Rs 204.70 crore despite 10.42% decline in revenue from operations to Rs 1,384.1 crore in Q3 FY25 over Q3 FY25. The scrip rallied 4.62% to settle at Rs 1,595.50 on the BSE. Powered by Capital Market - Live

Net profit of Gland Pharma rose 6.69% to Rs 204.69 crore in the quarter ended December 2024 as against Rs 191.86 crore during the previous quarter ended December 2023. Sales declined 10.43% to Rs 1384.05 crore in the quarter ended December 2024 as against Rs 1545.16 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1384.051545.16 -10 OPM %26.0123.06 - PBDT395.63388.50 2 PBT299.30283.16 6 NP204.69191.86 7 Powered by Capital Market - Live